[Can blood homocysteine explain the family history of vascular diseases?]

INTRODUCTION AND AIMS

Family history of vascular disease is an important risk factor for vascular disease, independent of conventional risk factors. Homocysteinemia, a newly defined risk factor, is caused by genetics, such as cystathionine beta synthase deficiencies, and metabolic deficiencies. With the present work we intend to study the influence of family history of vascular disease in homocysteinemia.

METHODS

We studied 204 normal persons (153 males), average age 38.7 +/- 10.9 years, in terms of family history of vascular disease (death due to myocardial infarction or a stroke), conventional risk factors, routine laboratory tests, fasting homocysteinemia and after oral methionine loading (0.1 g/Kg body weight). We compared laboratory results, conventional risk factors and homocysteinemia levels in persons with and without a family history of vascular disease. We performed covariance analysis to evaluate, in a multivariate model, factors that were related to basal or after methionine loading homocysteinemia.

RESULTS

35% of persons presented a family history of vascular disease (FHVD). Persons with FHVD presented higher age (45.6 +/- 8.9 versus 35.0 +/- 10.1, p < 0.001), and higher prevalence of hypertension (p = 0.002), dyslipidemia (p = 0.001), obesity (p = 0.03), and physical inactivity (p = 0.03). They presented a tendency, without statistical significance, to have a higher prevalence of diabetes and of hyperhomocysteinemia, and to present higher levels of basal and afterload homocysteinemia. Performing covariance analysis, basal homocysteinemia did not present any relation to FHVD. After methionine load homocysteinemia was strongly influenced by basal homocysteinemia (p = 0.0000), and significantly related to FHVD (p = 0.039).

CONCLUSIONS

Homocysteinemia cannot explain most of the risk of family history of vascular disease, not explained by conventional risk factors. The only significant relationship between homocysteinemia and FHVD was observed with afterload homocysteinemia in the multivariate model. FHVD is clearly related to conventional risk factors.

[Chronic obstructive pulmonary disease]

Chronic obstructive pulmonary disease (COPD) includes two entities, Chronic Bronchitis (C.B.) and Emphysema (E.), assembled by their common physiopathological feature, a progressive expiratory airflow obstruction. The presence of hyperreactivity is common and partial reversibility may be observed. The coexistence of CB and E. is largely the most prevalent. Cigarette smoking is the main risk factor per se or associated with other urban or occupational air pollutants. Therefore epidemiological COPD rats follow the prevalence of smoking habits in the population. The main goal of the strategy against the disease are preventive decisions and measures, as far as smoking is concerned. FEV1 values lower than 75% of FVC and a decline of FEV1 higher than 30 ml/year indicate a high risk of COPD among smokers. The assessment of FEV1 is important for monitoring and guiding treatment and is valid for grading the severity of COPD. Once the disease is confirmed the therapeutic skills are the following: to reduce the symptoms; to prevent and treat the exacerbations; to attenuate the functional impairment, both short and long term; to achieve better performance in daily activities and quality of life; to avoid and minimise the adverse effects of medication. The increase in life expectancy and the reduction of mortality are tangible goals related to a global and multidisciplinary approach. They mainly depend on smoking cessation, reducing the bronchial obstruction, and correcting chronic hypoxemia.

[Prognosis significance of blood homocysteine after myocardial infarction]

INTRODUCTION AND AIMS

Homocysteinemia is an independent risk factor of coronary artery disease and of myocardial infarction. In the present study we intend to relate fasting homocystein levels to prognosis after a myocardial infarction.

METHODS

From 1990 to 1992, we studied fasting homocysteinemia levels on a group of 112 patients aged under 56 years that had suffered a myocardial infarction between 3 and 12 months before. We obtained, the patients names, addresses, phone numbers and physicians' name. Seven years later (on average) we collected data regarding the patients evolution, consulting medical records, their physicians or by personal contact. We evaluated complications, namely mortality, vascular morbidity, such as unstable angina, re-infarction, stroke, and the need for invasive procedures (catheterism, PTCA, CABG). According to previous studies of the group, we used a cut-point of 10.10 mumol/L to define patients with normal or pathological levels of homocysteinemia. We excluded all patients that took vitamin B supplements, co-factors of HC metabolism, during this follow-up.

RESULTS

We were able to obtain data on 110 patients. Patients with normal HC levels (n = 62) presented less global complications (26 versus 72%, p < 0.0001), non significant tendency to have lower mortality (1.6 versus 6%), had lower morbidity (14 versus 36%, p < 0.01) and lower invasive procedure need (18 versus 48%, p < 0.001). In the group with pathological homocystein levels (n = 48), those with higher homocystein levels presented a higher degree of complications.

CONCLUSIONS

In this population with myocardial infarction under 56 years of age, a high homocysteinemia level is an important prognostic factor. This study suggests that we can improve the prognosis and decrease the complications after myocardial infarction by lowering elevated homocystein levels.

[Diastolic dysfunction and left ventricular hypertrophy in familial amyloidotic polyneuropathy: a cause-effect relationship?]

TTR Met30 Familial Amyloidotic Polyneuropathy of the Portuguese type (FAP) is an incapacitating and lethal hereditary disorder that affects predominantly young adults of both genders. Portuguese type FAP patients have sensory, motor and autonomic polyneuropathy. The generalised systemic amyloid infiltration involves the heart, leading to the characteristic granular bright sparkling echocardiographic pattern. LV wall thickening occurs in the late phases of the disease. LV diastolic dysfunction has been reported in the absence of systolic dysfunction; an abnormal diastolic transmitral flow pattern assessed by pulsed wave Doppler (PW) was described. PW is very much dependent on load conditions. Tissue Doppler imaging (TDI) has been used as a more reliable method to assess long axis diastolic function.

OBJECTIVE

1--To identify the incremental value of TDI in the assessment of diastolic function in FAP. 2--To correlate diastolic pattern abnormalities and left ventricular mass index (LVMI) in FAP patients.

METHODS

We performed a prospective evaluation of 24 consecutive FAP patients and selected 14 (sinus rhythm, age < 45 years). Diastolic function was assessed by PW and classified as normal (GI-E/A > 1) or abnormal (GII-E/A < 1). TDI was performed in 4 sites of the mitral annulus (septum, lateral, inferior, anterior). Velocities of the rapid filling wave (E') and atrial contraction wave (A') were measured and E'/A' calculated. In each site we considered the TDI as normal (E'/A' > 1) or abnormal (E'/A' < 1). The LVMI was calculated by Devereux's formula.

RESULTS

Age, gender and heart rate were similar in both groups. TDI at the septal mitral annulus was normal in all of the GI patients (E'/A': 1.29 +/- 0.19) and suggestive of abnormal LV relaxation in all of the GII patients (E'/A': 0.82 +/- 0.11, p < 0.0001). TDI revealed abnormal diastolic pattern when a restricted number of sites of the mitral annulus were assessed, even in GI patients and before PW abnormalities occurred. Fractional shortening (FS) and LVMI were similar in GI and GII (FS-GI: 45.5 +/- 5.3, GII 43.5 +/- 8.1%, p: NS; LVMI--GI: 66 +/- 9.3, GII: 67 +/- 3.0 g/m2 p: NS).

CONCLUSION

The assessment of mitral annulus motion has introduced new data in the study of diastolic function of FAP patients. An abnormal LV relaxation pattern occurred early in the evolution of the disease in patients with normal LVMI and systolic function.

[Influence of smoking on homocysteinemia at baseline and after methionine load]

INTRODUCTION AND AIMS

Homocysteinemia (HC) and smoking are both important risk factors for vascular disease. In the present study, we intend to evaluate the influence of smoking habits on HC values as well as on vitamins B6, B12 and folic acid, co-factors of HC metabolism.

METHODS

We measured fasting homocysteinemia (basal) and homocysteinemia 6 hours after an overload with 0.1 g methionine/kg body weight in 279 subjects. We also performed the dosage of plasma levels of B6 and B12 vitamins and of red cells folates. Smoking habits were inquired and the subjects were classified as non-smokers, current smokers or ex-smokers (if they had stopped smoking more than 1 month before the study). According to the smoking status, smokers were classified in three groups: less than 20 cigarettes a day, between 20 and 39 and 40 or more cigarettes a day. We studied basal and after methionine load homocysteinemia, B6, B12 and folic acid levels in each group.

RESULTS

Smokers presented significantly higher levels of basal and after methionine load homocysteinemia then non-smokers (10.6 +/- 4.9 vs 9.4 +/- 2.6, and 26.8 +/- 10.0 vs 24.3 +/- 7.4 mumol/L, respectively, p < 0.05 for both and B6 levels (29.2 +/- 12.0 versus 32.6 +/- 12.0 mumol/L, p < 0.05). B12 and folic levels were similar in the two groups. These results were quite similar either in the normal subjects or in the subjects with a history of a cardiovascular event. The subjects who smoked 40 or more cigarettes per day, compared with those who smoked less then 20 cigarettes per day, presented higher levels of basal homocysteinemia (12.4 +/- 2.9 vs 10.0 +/- 5.5 mumol/L, p < 0.05) and lower levels of B6 (24.7 +/- 8.1 vs 31.7 +/- 12.6 mumol/L, p < 0.05).

CONCLUSIONS

Smoking habits are related with the increase of basal and after methionine load homocysteinemia, probably because of a decrease in B6 vitamin levels. There is a proportional effect between the number of cigarettes smoked, B6 depletion and basal homocysteinemia increase. This study suggests that B6 vitamin supplements for smokers could decrease the vascular risk related with smoking habits.

[Homocysteinemia and vascular disease--a new risk factor is born]

In recent years there has been growing evidence that high levels of plasmatic homocysteine constitute an independent risk factor for early cardiovascular disease. In this article we review the main theories of atherosclerosis which take into account the proteins, namely homocysteine, homocysteine metabolism, the cause that may be responsible for high levels of homocysteinemia, the pathophysiologic mechanisms of vascular lesion induced by hyperhomocysteinemia, the clinical evidence that homocysteinemia constitutes a vascular risk factor and finally, the evidence that it is possible to control homocysteinemia with supplementation of co-factors of homocysteine metabolism, namely vitamin B6, B12 or folic acid.

[The effect of sex and menopause on basal blood levels of homocysteine and after methionine loading]

INTRODUCTION AND OBJECTIVES

We have already proved that basal and after load homocysteinemia are risk factors for vascular disease and it is also known that premenopausal women are relatively protected against this disease. The objective of this paper was the assess whether there are any differences in the plasma levels of homocystein which might contribute to explain the differences in the incidence of vascular diseases found in both sexes.

PATIENTS AND METHODS

Two hundred and four patients (153 males) without previous vascular disease were enrolled in the study. These patients were participating in a screening program for cardiovascular risk factors in a central hospital in Lisbon. We evaluated the basal homocysteinemia and homocysteinemia 6 hours after an oral load with methionine (0.1 g/kg body weight). Basal and after load homocysteinemia in men and women, as well as in women before and after menopause, was compared. Because homocysteinemia does not have a normal distribution, we used non-parametric statistical tests, namely the Mann-Whitney test.

RESULTS

Men had higher values for basal homocysteinemia than women (mean and standard deviation)--9.64 +/- 3.15 versus 8.56 +/- 2.82 mumol/l, (p = 0.0018)--as well as for after load homocysteinemia--24.40 +/- 7.84 versus 23.71 +/- 10.16 mumol/L, non significant difference. Premenopausal women (n = 42) had lower basal homocysteinemia values than post menopausal women (n = 9)--8.41 +/- 3.02 versus 9.23 +/- 1.38 mumol/L, p < 0.05--and similarly after load homocysteinemia values--23.86 +/- 10.65 versus 23.01 +/- 7.47 mumol/L.

CONCLUSIONS

Basal homocysteinemia is significantly higher in men than in women. After menopause, basal homocysteinemia levels increase significantly in women, approaching those in men. The levels of after load homocystein are not dependent on sex or pre- or postmenopausal condition. Homocysteinemia might explain, at least partly, the differences in the incidence of vascular disease in both sexes and the increased vascular risk in postmenopausal women.

[The diagnostic and prognostic value of the 12-lead electrocardiogram in assessing the severity of coronary disease in the acute phase of an acute myocardial infarct]

The conventional twelve-lead electrocardiogram (ECG) still is the cheapest, most used and absolutely essential diagnostic method for the acute phase of myocardial infarction (MI) allowing risk stratification and coronary prognostic evaluation in this phase mainly by the localization of the ST segment depression and/or T wave inversion (ST/T changes) not related to the infarct area in Q-Wave MI or at any localization in case of non-Q wave MI. The etiology and pathophysiology of these ST/T changes in the setting of MI has been controversial. With the objective of determining ECG prognostic and diagnostic value, 70 patients (Pts) (59 men and 11 women, mean age 58 + 13) admitted in the acute phase of MI were studied with revision of acute phase ECG ST/T changes. All patients underwent coronary angiography and ventriculography at the moment of hospital discharge. Patients were divided into two classifications: A) MI localization: A1--Q-wave MI (anterior--20 pts, inferior--29 pts, lateral--1 pt); A2--non-Q wave--20 pts. B) Evidence of ST/T changes outside the infarct area in Q wave MI or at any localization in non-Q wave MI (group B1--with ST/T changes, group B2--without ST/T changes). We correlated the angiographically documented coronary artery disease in groups with ST/T changes and their localization.

RESULTS

A1) Anterior MI group: in the 6 pts (30%) with "opposite" (inferior) ST/T changes, right coronary artery (RCA) disease was documented in 5 and in the other 14 patients the RCA did not show significant lesions. Inferior MI group: in the 24 Pts (83%) with "opposite" (precordial) ST/T changes. 23 of them had angiographic correlation (left anterior descending (LAD) and/or circumflex (CX) artery disease). Lateral MI group: one Pt with anterior wall ST/T changes and LAD and CX disease. A2) Non-Q wave group: in 13 pts (87%) the diseased vessels were correlated with the site of ST/T changes. B1) Q-Wave AMI: left main and 3-vessel disease in 2 pts, 3-vessel disease in 17 pts, 2-vessel disease in 9 pts, 1-vessel disease in 2 pts and non-significant disease in one pt. Non-Q wave MI: left main and 3-vessel disease in 1 pt, 3-vessel disease in 7 patients, 2-vessel disease in 3 pts and 1-vessel disease in 4 pts. B2) non-Q Wave MI: 3-vessel disease in 5 pts, 2-vessel disease in 7 pts, 1-vessel disease in 6 pts and non-significant disease in 1 pt. Non-Q wave MI: 2-vessel disease in 2 pts and non-significant disease in 1 pt.

IN CONCLUSION

When pts were divided according to MI localization, a correlation was found between the ST/T changes outside the infarct area with CAD in 91% of Pts in the Q-Wave infarction group, with more significance in inferior and lateral MI. In the non-Q wave group, we found correlation between the a coronary lesions and the localization of ST/T changes in 87% of the pts. The pt group with ST/T changes presented, when compared with the pt group without these changes, evidence of more severe coronary artery disease (CAD): 3 vessels or left main with 3 vessel disease. However, only in the Q-Wave infarction group was a statistically significant difference found between the group with ST/T changes compared to the group without these changes, concerning to the existence of more severe coronary disease.

[Severe thrombocytopenia associated with Abciximab therapy--apropos a clinical case]

The authors present the case of a 52-year-old male patient with severe coronary artery disease, submitted to percutaneous transluminal coronary angioplasty on a type C right coronary artery lesion. The use of a platelet glycoprotein receptor IIb-IIIa inhibitor, Abciximab, led to severe thrombocytopenia, treated only with platelet concentrate transfusions and with complete recovery. We also review the principal characteristics of the drug, its main indications and side effects. Severe thrombocytopenia has rarely been described in the literature.

[Myocardial viability. Concept, physiopathology. Methods and diagnostic value]

The purpose of this study is to describe the concept and physiopathology of myocardial viability to provide rational use of diagnostic methodologies and their value. Great relevance has been given to the diagnosis of myocardial viability since it was published in 1982, because of the consequences of therapeutic decisions and prognostic evaluation on the patient's quality of life. The cost/benefit values of these methodologies must be adequate in clinical terms and carefully assessed.

[Individualized monitoring of the therapy with gentamycin using pharmacokinetic methods. Which method to choose?]

Gentamicin has an excellent cost/efficacy ratio for gram negative infections treatment. Its use is often limited in clinical practice by its narrow safety margins and a high incidence of toxicity. Gentamicin related nephrotoxicity is a major adverse effect, mostly in patients with other concomitant potential risk factors. As many other Authors we have found in our Internal Medicine Service during 1992 a gentamicin related nephrotoxicity incidence of 22.5%. Various empiric methods and nomograms have shown a significant incidence of error in predicting individualized gentamicin dosage regimens. Pharmacokinetics methods have demonstrated much better results regarding efficacy and toxicity. The aim of this prospective study carried out during 1993-1994 was to individualize by pharmacokinetics methods dosage regimens of gentamicin in patients with one or more concomitant risk factors of nephrotoxicity. The purpose of pharmacokinetics dosage regimens has been to achieve trough serum concentrations of gentamicin in therapeutics range-0.5 to 2 micrograms/ml-on the first 24 to 48 hours of treatment, and the maintenance in this range during all the treatment, avoiding both toxic and under therapeutic levels. The incidence of gentamicin related nephrotoxicity has been evaluated in this population. Twenty patients were studied: 18 males and 2 females aged 59.6 years (19 to 85). All had one or more potential risk factors for nephrotoxicity-65 years or more: 13, previous renal failure: 6, other nephrotoxic drugs: 10, diuretics: 4, dehydration: 5, congestive heart failure: 5, diabetes: 3, hypertension: 3. For the first 10 patients gentamicin dosage regimens have been determined by Sawchuk-Zaske pharmacokinetics method and for the subsequent 10 patients by Bayesian method. The two subpopulations had no significant differences regarding mean age, sex and potential risk factors for nephrotoxicity. Results of Sawchuk-Zaske method: 53 trough gentamicin serum concentration were obtained; 86.8% were within the therapeutic range, 7.5% were toxic and 5.7% were under therapeutic. Results of Bayesian method: 44 determinations of gentamicin through concentrations were obtained; 86.3% within therapeutic range, 2.4% were toxic and 11.3% were under therapeutic. A great variability in pharmacokinetic patient's profile has been found and explains the great variability of individualized dosage regimens of gentamicin (30 to 320 mg/day). No patients had gentamicin related nephrotoxicity. Both pharmacokinetics methods lead to a efficient and save employment of gentamicin in patients with previous renal failure and other potential risk factors for nephrotoxicity.

[Severe poisoning by organophosphate compounds. An analysis of mortality and of the value of serum cholinesterase in monitoring the clinical course]

Ingestion of organophosphate (OP) compounds usually results in severe poisoning. We undertook a retrospective study of 52 consecutive patients admitted with severe OP poisoning to determine the value of serum cholinesterase (SChE) in monitoring clinical course. Considering survivors and non-survivors, we evaluate clinical and laboratory baseline characteristics, severity scores (APACHE II, SAPS II), atropine rate (mg/h), SChE evolution at 24, 72 and 120 h and final SChE (SChE at the day of discharge or death). Mortality in the ICU was 28.9% (n = 15). In both groups SChE showed a trend to increase. In survivors, SChE recovery was statistically significant for SChE 24h-SChE 72 h, SChE 24 h-SChE 120 h and SChE initial-SChE 120 h (p = 0.008, p = 0.00003, p = 0.0002 respectively). In this group a simultaneous decrease in atropine requirements was registered. In non-survivors, the rate of atropine remained unchanged up to 120 h. Three groups could be defined in non-survivors according to their final SChE and day of death. Non-survivors-1 (death in the first 24h; 2 patients) and non-survivors-2 (death after the first 24 h; 5 patients) had a final SChE below 10% of normal SChE activity and statistically different from survivors' final SChE. Non-survivors-3 (8 patients) had a final SChE similar to the survivors and death was due to sepsis and multiple organ failure (MOF). We conclude that SChE is useful in OP poisoning diagnosis and also in monitoring clinical course. SChE recovery above 10% of normal seems to correlate with good prognosis. Sepsis and MOF were important determinants of mortality.

[Homocysteinemia as a risk factor in early cerebrovascular disease]

PURPOSE

To determine whether hyperhomocysteinemia represents a risk factor of early thrombotic cerebrovascular disease.

METHOD

In a group of patients under 55 years of age (n = 33, 19 males) which had suffered a stroke from 3 months to 1 year before the study, defined by clinical criteria and presence of cerebral infarction confirmed by tomography, without history or predisposition to embolic disease. The patients were matched with a group of normal controls of checkup program, in terms of age, and sex. Patients and controls with a history of alcoholism, clinical or laboratory signs of renal or hepatic insufficiency or with a history of recent ingestion of Group B vitamins were excluded since these conditions would influence homocysteinemia levels. We measured the plasmatic basal homocysteinemia of patients and controls (HC) and 6 hours later a methionine overload of 0.1 g/Kg body weight (LOAD HC).

RESULTS

Patients; Controls; Signific.; Age 46.0 +/- 7.7; 45.9 +/- 7.8; NS; Basal HC. 10.1 +/- 3.4; 8.5 +/- 1.7; p < 0.05; Load HC 28.0 +/- 7.6; 22.7 +/- 5.5; p < 0.01.

CONCLUSION

In this study hyperhomocysteinemia appears as a risk factor for thrombotic cerebrovascular disease before the age of 55;-The measurement of homocysteinemia after the methionine loading test was more discriminative than the basal measurement;-A larger number of patients and controls will be necessary to establish the relative importance of homocysteinemia among other vascular risk factors in cerebrovascular disease.

[Homocysteinemia as a risk factor for early myocardial infarct--a case-control study]

PURPOSE

To investigate if hyper-homocysteinemia represents an independent risk factor of early coronary disease.

METHODS

We studied a group of patients under 45 years old, that suffered a myocardial infarction from 3 months and 1 year before the study. The patients were matched with a group of normal controls of a check-up program, in terms of age, sex, smoking habits, presence of hypertension, obesity, (Quetelet Index), presence of diabetes, basal glycemia, total cholesterol, LDL and HDL cholesterol. Later we measured to patients (Pts) and controls (Cts) the plasmatic basal homocysteinemia (B HC) and 6 hours after a methionine overload of 0.1 g/kg body weight (L HC).

RESULTS

[table: see text]

CONCLUSIONS

In this study hyper-homocysteinemia appears as an independent risk factor of early coronary disease. The measurement of homocysteinemia after the methionine loading test was more discriminative than the basal measurement.

[The evaluation of the hemodynamic effects of captopril one year after a myocardial infarct]

In the present study, the authors evaluate the haemodynamic effects of continuous captopril therapy during one-year after a first anterior myocardial infarction (MI). Haemodynamic measurements are made during the first 48 hours after de MI and repeated one year later. Patients are divided in two groups: The first group had therapy with acetylsalicylic acid (ASA) and isosorbide dinitrate (ISDNI) and the second group had therapy with ASA, ISDNI and captopril. From their results the authors conclude that captopril helps peripheral resistances elevations, and that this is one of the mechanisms by which it can have a favourable effect after an anterior MI.

[Heart failure and the clinician at the end of the 20th century]

Congestive heart failure represents a clinical syndrome whose symptoms and signs result from different etiopathogenic and pathophysiological mechanisms. Diagnosing congestive heart failure remains mainly a matter for accurate clinical methodology. Therapeutical approaches to congestive heart failure require a profound knowledge of the behaviour of each system and mechanism involved in the process, namely neurohumoral activation, dysautonomia and endothelial responses, besides renal, skeletal muscle, cardiac and pulmonary participation. So, the treatment of congestive heart failure is always multifactorial. Preventing heart failure requires also an accurate knowledge of those mechanisms, in order to apply the most appropriate measures to stop vascular and cardiac remodeling.

[Unstable angina. An evaluation of a diagnostic and therapeutic methodology]

The authors describe the diagnostic and therapeutic management of 55 patients with the diagnosis of unstable angina admitted at a medical intensive care unit. According to Braunwald classification, 52 patients had primary angina and the remaining three had post-infarction angina. Risk stratification was based on non invasive procedures such as 2D echocardiogram and exercise test after clinical stabilization. Coronary angiography was performed in all patients. Most of the patients needed revascularization: 62% by percutaneous transluminal coronary angioplasty (PTCA) and 13% were submitted to coronary artery by-pass graft (CABG). None of the patients died during hospitalization.

["Severe" congestive heart failure at a medical center]

Heart failure (HF) is a dynamic clinical syndrome depending on multiple hemodynamic and neurohormonal factors. This syndrome concerns not only left ventricular systolic dysfunction but also left ventricular diastolic dysfunction and right ventricular dysfunction. Clinical features and therapeutic approaches are different for each of them. NYHA class IV is just one of the various prognostic factors of heart failure; consequently, severe heart failure is not synonymous of NYHA class IV.

OBJECTIVE

To study hospitalised patients with heart failure in NYHA class IV, in order to characterise the predominant dysfunction, and analyze evolution and mortality.

DESIGN

A retrospective analysis of a prospective study.

SETTING

Hundred and eight hospitalised patients (1985-89). Patients with chronic obstructive pulmonary disease and acute myocardial infarction were excluded.

PATIENTS

Sixty nine patients: 29 female and 40 male, aged 18 to 81 years old (m = 59 +/- 15.5).

METHODS

Patients were clinically examined and had chest radiographs, electrocardiogram and M + 2D mode echocardiogram. Three groups were identified: Group I-patients with predominant left ventricular systolic dysfunction; Group II-patients with predominant left ventricular diastolic dysfunction; Group III-patients with predominant right ventricular dysfunction.

RESULTS

41% of the patients had coronary artery disease; 44%, valvular heart disease; 11.8% dilated cardiomyopathy; 8.7% hypertrophic cardiomyopathy; 8.7% hypertensive cardiomyopathy. Fifty five percent of the patients were in group I and the major aetiology were coronary artery disease and valvular heart disease; 25% of the patients were in group II and the major aetiology were coronary artery disease and hypertrophic cardiomyopathy; 20% of the patients were in group III, all had valvular heart disease. The global mortality during the hospitalisation period was 15.9%, mostly group III (29%) and II (17%).

CONCLUSIONS

Heart failure patients in NYHA class IV formed an heterogeneous group, requiring individualised therapeutic approaches. Left ventricular systolic dysfunction was the major pathophysiological mechanism, however, diastolic dysfunction and right ventricular dysfunction were frequent. Coronary artery disease presented as a frequent aetiology of heart failure, resulting in diastolic and/or systolic dysfunction. Valvular heart disease can be present as left ventricular systolic or diastolic dysfunction or as a right ventricular dysfunction, depending on the valvulopathy and the time of evolution. Echocardiography, in association with clinical features, has been very useful for each patient approach, allowing HF aetiology and pathophysiological mechanisms characterisation. The low mortality observed in this study was related certainly to the correction of precipitating factors, together with early etiologic diagnosis and pathophysiological characterisation, and adequate individualised treatment.

[Risk stratification in non-Q-wave myocardial infarct]

There was been some controversy about non-Q wave myocardial infarction, its evolution and prognosis. The most recent studies showed that, in spite of the low immediate mortality in non-Q wave myocardial infarction, the long-term risk of ischaemia, reinfarction or sudden death is equal or even greater than in the Q-Wave myocardial infarction. In order to define an adequate ischaemic risk stratification strategy in the post non-Q wave myocardial infarction without complications, the authors studied 21 patients who were submitted to treadmill exercise test and coronary angiography within 30 days after the acute event. Of the 17 patients with positive stress testing, 14 showed significant relationship between ischaemic area detected in the stress testing and the anatomic localization and severity of the lesions in the coronary angiography (chi 2 = 14,875; p < 0.006). Revascularization therapy (PTCA or bypass surgery) was very high in this group of patients (47.6%). From the date obtained the authors conclude that it is not necessary to use invasive studies in every patient that has suffered from non-Q wave myocardial infarction without complications, since the stress testing showed high sensitivity (94.4%), specificity (75%) and high predictive value (100%) in the ischaemic risk stratification.

[A case of "fluctuating" arterial hypertension]

A case of arterial hypertension with clinical and laboratory findings typical of renovascular hypertension is presented. The situation normalized after prolonged rest and exacerbated on orthostatism. Directed study demonstrated a giant pseudo cyst of pancreas that caused the situation which normalized after elective pancreatectomy. A brief comment and a review of literature is presented.

[Ibopamine in the treatment of congestive heart failure. Multicenter follow-up study]

OBJECTIVE

To assess safety and efficacy of ibopamine, 200 mg TID, added to conventional treatment of congestive heart failure.

DESIGN

A prospective, longterm, open study over two years (1986-88). A multicenter trial.

SETTING

Outpatients of Departments of Internal Medicine of S. Francisco Xavier Hospital and Sta. Maria Hospital, and Departments of Cardiology of Sta. Cruz Hospital and Hospital Militar Principal, Lisbon.

PATIENTS AND METHODOLOGY

63 patients, 49 males from 34 to 80 years (m = 55.6 +/- 11.36) and 14 females from 41 to 80 years (m = 63 +/- 10.2), with congestive heart failure, NYHA class II in 52 patients (82.5%) and NYHA class III in 11 patients (17.5%) with a mean disease duration of 47.9 months entered into the study. Digoxin, diuretics, nitrates and antiarrhythmic drugs were allowed as concomitant therapy. Patients carried out clinical examination, ECG and laboratory tests monthly and X-Ray at the beginning and at the end of each year of the study.

RESULTS

42 patients completed one year of treatment and 20/42 continued for an additional year, 17 patients completed this second year of follow-up. From the 42 patients who completed the first year period, the NYHA class changed from II to I in 17/38 from II to III in 2/38 patients from III to II in 3/4 patients, and from III to IV in one patient. Twenty patients dropped during the first year of treatment. Six for non-compliance (less than 80% of the treatment). Two were submitted to cardiac valve surgery. Seven had cardiovascular clinical events: one ventricular tachycardia, one atrial fibrillation, one pulmonary edema, one patient had no therapeutic effect, two patients had anxiety and fatigue and one patient died suddenly. One diabetic patient had uncontrolled hyperglycemia. One patient had gastric ulcer. Two had nausea and vomiting. Dysrhythmia and nausea and vomiting were the only clinical events, considered, respectively, possibly related and related, to ibopamine. During the second year of treatment 9/11 patients were stabilized in NYHA class I and 6/9 in NYHA class II, one patient changed from class II to class I, and one patient changed from class I to class II of the NYHA. Three patients did not complete the second year of treatment; one due to abnormal creatininemia; one for probable pulmonary embolism with CHF worsening; the third died suddenly. None of these events was considered related to ibopamine. Heart rate, arterial pressure, laboratory values and cardiothoracic index did not vary over the two years of the study.

CONCLUSIONS

This has been the first study with data from patients treated with 200 mg TID of ibopamine during two years. Ibopamine has been shown to be a safe and useful drug added to conventional treatment of cardiac heart failure. Clinical events were few and well controlled after ibopamine interruption.

[Myocardiopathy caused by Portuguese-type familial amyloidotic polyneuropathy. Sequential morphologic and functional study of 60 patients]

AIM OF THE STUDY

To assess the cardiac involvement of familial amyloidotic polyneuropathy--Portuguese type (FAP) in a prospective study.

INTRODUCTION

FAP is a sensitive, motor and autonomic familial polyneuropathy, due to amyloid deposits on nerve and vascular structures, related to abnormal transthyretin synthesis. FAP is a progressive systemic disease. The associated cardiomyopathy is well characterized in the Japanese form, but studies on FAP--Portuguese type cardiomyopathy remains controversial, regarding its occurrence and clinical and morphofunctional aspects.

POPULATION

The Authors studied 60 Portuguese caucasoid patients, belonging to 55 different families: 23 women from 27 to 67 years old (m = 40.78 +/- 18.4) and 37 men, from 31 to 60 years old (m = 40.8 +/- 12.8). The diagnosis was established by characteristic clinical aspects, electromyograms and nerve or gut biopsies, positive for amyloid. Patients were classified in phases from I to VI according to the severity of neurological involvement and disability.

METHODS

All the patients carried out clinical evaluation, thorax X-Ray, conventional EKG, Holter EKG (20-24 hours), M + 2D echocardiography and phonocardiography. Morphological and functional data were obtained from 85 echocardiographic recordings; special attention was paid to the evidence of structural abnormalities, evaluation of internal chamber dimension, left ventricular mass and systolic function indexes (left ventricular fractional shortening, left ventricular ejection fraction, left ventricular end-systolic stress index and Vcf).

CONCLUSIONS

Suggestive aspects of pericardial and myocardial amyloid infiltration were found even in the earliest phases of the disease; all the records of patients in advanced phases (III to VI) were abnormal. The most frequent abnormalities founded were: a bright sparkling pericardial and myocardial echo pattern and increased ventricular wall thickness, with increased left ventricular mass index in 85% of patients in phases III to VI. Vcf was abnormally increased when plotted together with left ventricular end-systolic stress index, which was normal or decreased, probably reflecting "excessive" inotropism, in 1/3 of patients in phases III to VI. Systolic function was never depressed; no cardiac chamber enlarged. So, this study points out the presence of an infiltrative and/or hypertrophic cardiomyopathy in FAP--Portuguese type; suggestive aspects of diastolic dysfunction and decrease in systolic function were recorded. However, in the clinical setting of FAP, symptoms and signs like dyspnea, fatigue, oedema, may not be diagnosis of congestive heart disease.